Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

Leukemia

Volumn 27, Issue 7, 2013, Pages 1538-1547

  Weber, G ^a,b,c   Gerdemann, U ^a,b   Caruana, I ^a,b   Savoldo, B ^a,b   Hensel, N F ^c   Rabin, K R ^b   Shpall, E J ^d   Melenhorst, J J ^c   Leen, A M ^a,b   Barrett, A J ^c   Bollard, C M ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytotoxic T cells; Graft versus leukemia effect; Immunotherapy; Myeloid leukemia; Stem cell transplantation; Tumor associated antigens

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 2; LEUKOCYTE ELASTASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELANOMA ANTIGEN 3; MYELOBLASTIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPITOPE MAPPING; GRAFT VERSUS LEUKEMIA EFFECT; HLA SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MYELOID LEUKEMIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CELL LINE; DENDRITIC CELLS; EPITOPE MAPPING; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; LEUKOCYTE ELASTASE; MEMBRANE GLYCOPROTEINS; MYELOBLASTIN; PEPTIDE FRAGMENTS; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; WT1 PROTEINS;

EID: 84880259968     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.66     Document Type: Article

References (46)

1. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008; 142: 877-888.
2. Montagna D, Maccario R, Locatelli F, Montini E, Pagani S, Bonetti F et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 2006; 108: 3843-3850.
3. Burnett AK, Knapper S. Acute Myeloid Leukemia. In: Treleaven J, Barrett AJ eds. Haematopoietic Stem Cell Transplantation in Clinical Practice. Elsevier, 2009.
4. Porter DL, June CH. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: T' it up! Bone Marrow Transplant 2005; 35: 935-942.
5. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol 2008; 21: 437-453.
6. Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H et al. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLADRB1* 0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 2007; 30: 282-293.
7. Weber G, Karbach J, Kuci S, Kreyenberg H, Willasch A, Koscielniak E et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 2009; 23: 1634-1642.
8. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171-179.
9. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242.
10. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E et al. Graft-versusleukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110: 1924-1932.
11. Rezvani K, Price DA, Brenchley JM, Kilical Y, Gostick E, Sconocchia G et al. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy 2007; 9: 245-251.
12. Qazilbash M, Wieder E, Rios R, Lu S, Kant S, Giralt S et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. ASH Annu Meet Abstr 2004; 104: 259.
13. Fujiwara H, El OF, Grube M, Price DA, Rezvani K, Gostick E et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood 2004; 103: 3076-3083.
14. Rezvani K, Yong AS, Mielke S, Savani BN, Jafarpour B, Eniafe R et al. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother 2012; 61: 1125-1136.
15. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S et al. Ex-vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009; 113: 2245-2255.
16. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918.
17. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11(Pt 1): 8799-8807.
18. Schmitt M, Casalegno-Garduno R, Xu X, Schmitt A. Peptide vaccines for patients with acute myeloid leukemia. Expert Rev Vaccines 2009; 8: 1415-1425.
19. Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol 2011; 89: 396-407.
20. Jiang YZ, Barrett J. The allogeneic CD4+ T-cell-mediated graft-versus-leukemia effect. Leuk Lymphoma 1997; 28: 33-42.
21. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 2011; 19: 2258-2268.
22. Hoffmeister B, Kiecker F, Tesfa L, Volk HD, Picker LJ, Kern F. Mapping T cell epitopes by flow cytometry. Methods 2003; 29: 270-281.
23. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
24. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367.
25. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculturederived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
26. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
27. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776.
28. Bornhauser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 2011; 117: 7174-7184.
29. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114: 4283-4292.
30. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33: 305-315.
31. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114: 1958-1967.
32. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012; 20: 1622-1632.
33. Bollard CM, Gottschalk S, Helen HM, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy 2011; 13: 518-522.
34. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-2845.
35. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M et al. Activationinduced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007; 110: 201-210.
36. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK et al. An Epstein- Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97: 835-843.
37. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y et al. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 2010; 12: 1056-1062.
38. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009; 113: 66-74.
39. Yong AS, Stephens N, Weber G, Li Y, Savani BN, Eniafe R et al. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 2011; 25: 629-637.
40. Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F et al. RHAMMR3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008; 111: 1357-1365.
41. Niens M, van den BA, Diepstra A, Nolte IM, van der SG, Gallagher A et al. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev 2006; 15: 2280-2284.
42. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics 2000; 51: 99-107.
43. Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitopespecific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 2012; 120: 1633-1646.
44. Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L. Prediction of an HLA-DRbinding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002; 51: 271-281.
45. Lacey SF, La RC, Kaltcheva T, Srivastava T, Seidel A, Zhou W et al. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood 2011; 118: 2159-2169.
46. Piesche M, Hildebrandt Y, Chapuy B, Wulf GG, Trumper L, Schroers R. Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3. Vaccine 2009; 27: 4718-4723.